Norway Pet and Animal Brands Clinch ‘Brand of the Year’ Awards
Today, the prestigious World Branding Awards, the ultimate global brand recognition accolade – now in its 13th edition, saw 150 brands from 41 countries named “Brand of the Year” in a first-ever virtual awards ceremony held in the history of the Awards. The brands were nominated by over 115,000 consumers from six continents for the special biennial Animalis edition which focuses on awarding the best pet and animal brands from around the world.
Animal Planet, BuddyRest, FRONTLINE, KONG, ORIJEN, Pedigree, Petplan, PURINA Friskies, Rogz, Tetra, and Whiskas, amongst others, were proudly announced as this year’s Global Tier winners.
Regional Tier winners included Vitakraft and zooplus (Germany), Happi Doggy and Kit Cat (Singapore), and PetSmart (USA), amongst others.
Appetitt (Dog Food – Dry/Kibble) was announced as a proud National Tier winner from Norway, amongst others
Winners are uniquely judged through three streams: brand valuation, consumer market research, and public online voting. Seventy percent of the scoring process comes from consumer votes.
“The Animalis Edition of the Awards honours the best brands in the animal and pet industries around the world and recognises those who have remained at the forefront of consumers’ minds. Given the challenges the global pandemic has caused to businesses, it is an astounding success, to say the least,” said Richard Rowles, Chairman of the World Branding Forum.
“The Animalis Edition of the Awards is very competitive. Brands that win show that they have set the standard for what is expected of other pet and animal brands to be at the top of their game,” said Danny Pek, Chief Executive of the Forum.
The award ceremony saw entrepreneur, Lara Morgan, and media vet, Joe Inglis, deliver keynote speeches to guests.
Now in its eighth year, the awards are organised by the World Branding Forum, a global non-profit organisation dedicated to advancing branding standards.
For more information and the full list of winners, visit awards.brandingforum.org.
About the World Branding Forum
The World Branding Forum (WBF) is a registered global non-profit organisation. Its aims and activities are to raise the standards in branding for the good of the industry as well as consumers. The WBF produces, manages and supports a wide range of programmes covering research, development, education, recognition, networking and outreach. For more information, visit brandingforum.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005353/en/
Contact information
Press
Peter Michaels
peter.michaels@brandingforum.org
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new